Format

Send to

Choose Destination
See comment in PubMed Commons below
CNS Drugs. 2005;19(10):805-19.

COX-2 inhibitors as adjunctive therapy in schizophrenia: rationale for use and evidence to date.

Author information

1
Department of Psychiatry and Psychotherapy, Ludwig-Maximilan University of Munich, Munich, Germany.

Abstract

A better understanding of the human immune system and its complex interactions has resulted in new insights into the pathoaetiological mechanisms of psychiatric disorders. As a result, new treatment options are being explored. Several findings suggest that an imbalanced immune response is involved in the pathophysiology of schizophrenia. COX-2 inhibitors are known to influence the immune system in a way that may redirect this imbalance. Based on these suggestions, the COX-2 inhibitor celecoxib has been tested as a possible adjunctive therapeutic approach in the treatment of schizophrenia. While the first trial using celecoxib as add-on therapy to an atypical antipsychotic showed a significant beneficial effect, recent studies demonstrated that this effect may be limited to patients with recent-onset schizophrenia.

PMID:
16185091
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center